Jan P. van Meerbeeck
Department of Respiratory Medicine 7K12IE
Ghent University Hospital
De Pintelaan 185
9000 Ghent
Belgium
Name/email consistency: high
- The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Hollevoet, K., Nackaerts, K., Thas, O., Thimpont, J., Germonpré, P., De Vuyst, P., Bosquée, L., Legrand, C., Kellen, E., Kishi, Y., Delanghe, J.R., van Meerbeeck, J.P. Chest (2012)
- Small-cell lung cancer. van Meerbeeck, J.P., Fennell, D.A., De Ruysscher, D.K. Lancet (2011)
- Malignant pleural mesothelioma: the standard of care and challenges for future management. van Meerbeeck, J.P., Scherpereel, A., Surmont, V.F., Baas, P. Crit. Rev. Oncol. Hematol. (2011)
- Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments. van Meerbeeck, J.P., Surmont, V.F. Lung. Cancer (2009)
- What is the optimal treatment of stage IIIA-N2 non-small-cell lung cancer after EORTC 08941?. Van Meerbeeck, J.P., De Pauw, R., Tournoy, K. Expert. Rev. Anticancer. Ther (2008)
- Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. van Meerbeeck, J.P., Kramer, G.W., Van Schil, P.E., Legrand, C., Smit, E.F., Schramel, F., Tjan-Heijnen, V.C., Biesma, B., Debruyne, C., van Zandwijk, N., Splinter, T.A., Giaccone, G. J. Natl. Cancer Inst. (2007)
- Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma. van Meerbeeck, J.P., Boyer, M. Lung. Cancer (2005)
- Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. van Meerbeeck, J.P., Gaafar, R., Manegold, C., Van Klaveren, R.J., Van Marck, E.A., Vincent, M., Legrand, C., Bottomley, A., Debruyne, C., Giaccone, G. J. Clin. Oncol. (2005)
